Level Four Advisory Services LLC Increases Stake in Pfizer Inc. $PFE

Level Four Advisory Services LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.3% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 163,054 shares of the biopharmaceutical company’s stock after purchasing an additional 8,190 shares during the quarter. Level Four Advisory Services LLC’s holdings in Pfizer were worth $4,132,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Clarity Asset Management Inc. bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $27,000. Gould Capital LLC raised its position in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the first quarter valued at approximately $27,000. North Capital Inc. bought a new stake in shares of Pfizer during the first quarter valued at approximately $28,000. Finally, Bayforest Capital Ltd bought a new stake in shares of Pfizer during the first quarter valued at approximately $28,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on PFE shares. Jefferies Financial Group increased their target price on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, May 21st. Wolfe Research increased their target price on Pfizer from $22.00 to $23.00 and gave the company an “underperform” rating in a research report on Wednesday, April 30th. Leerink Partners lowered their target price on Pfizer from $28.00 to $26.00 and set a “market perform” rating for the company in a research report on Wednesday, April 30th. Berenberg Bank lowered their target price on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Thursday, May 29th. Finally, Morgan Stanley increased their target price on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.12.

Pfizer Stock Up 0.2%

NYSE PFE opened at $25.3750 on Thursday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company has a fifty day moving average of $24.66 and a two-hundred day moving average of $24.42. The firm has a market capitalization of $144.27 billion, a price-to-earnings ratio of 13.50, a PEG ratio of 0.90 and a beta of 0.52. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer’s payout ratio is presently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.